156001-49-9

Basic information

• Product Name: 5-Bromo-2-(bromomethyl)toluene, 4-Bromo-1-(bromomethyl)-2-methylbenzene
• Synonyms: 4-Bromo-2-methylbenzyl bromide;5-Bromo-2-(bromomethyl)toluene, 4-Bromo-1-(bromomethyl)-2-methylbenzene;Benzene, 4-bromo-1-(bromomethyl)-2-methyl-;4-bromo-1-(bromomethyl)-2-methylBenzene
• CAS NO: 156001-49-9
• Molecular Formula: C₈H₈Br₂
• Molecular Weight: 263.95712
• Mol File: 156001-49-9.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 280.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.743±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 5-Bromo-2-(bromomethyl)toluene, 4-Bromo-1-(bromomethyl)-2-methylbenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-(bromomethyl)toluene, 4-Bromo-1-(bromomethyl)-2-methylbenzene(156001-49-9)
• EPA Substance Registry System: 5-Bromo-2-(bromomethyl)toluene, 4-Bromo-1-(bromomethyl)-2-methylbenzene(156001-49-9)

Safety Data

• Hazardous Substances Data: 156001-49-9(Hazardous Substances Data)

Upstream product

• 17100-58-2 4-bromo-2-methylbenzyl alcohol 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 68837-59-2 4-bromo-2-methylbenzoic acid 

Downstream Products

• 215800-05-8 2-(4-bromo-2-methylphenyl)acetonitrile 
• 958646-47-4 (4-bromo-2-methylphenyl)acetic acid methyl ester 
• 1261653-82-0 (4-cyano-2-methylphenyl)acetic acid methyl ester 
• 1428761-11-8 [4-(N-hydroxycarbamimidoyl)-2-methylphenyl]acetic acid methyl ester 
• 1428761-12-9 [2-methyl-4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenyl]acetic acid methyl ester 

Relevant articles and documents

COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY

This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, CF3 and OCF3; -Y- represents formula (IA) R3 represents hydrogen, fluoro, chloro or C1-4alkyl; R4a and R4b each independently represent hydrogen, C1-4alkyl, C1-4alkoxy, CF3 or halo; and R5 represents a group Z-X; wherein Z is absent or represents (CH2)2 or O; and X represents formula (IB) wherein: J and L both represent CH, or one of J and L represents CH and the other represents N; when both J and L represent CH, R6 represents hydrogen, halo, CF3, C1-4alkyl or C1-4alkoxy in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, OCF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; or when one of J or L represents N, R6 represents hydrogen or halo in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; and R8 and R9 are independently selected from hydrogen and C1-4alkyl; or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in medicine, and processes for their preparation.